A particularly strong vote of confidence has been registered in the biotech company Scribe Therapeutics ($SCTX) as its director, Behzad Aghazadeh, acquired a massive $36.3 million worth of shares in the open market. The transaction, involving the purchase of 2,391,238 shares, was reported to the SEC on July 24, 2026. A purchase of this magnitude by an insider is generally considered a highly positive signal, as it reflects the director's belief in the company's future growth potential.

Aghazadeh, as a board member, is in a unique position to have in-depth knowledge of the company's operations, product developments, and business strategy. Such a significant purchase with his personal funds underscores his commitment and perception of Scribe Therapeutics' true value, a company focused on developing genome editing technologies.

Individual traders can learn from such a move that insider buying is an important indicator. While insiders can sell shares for many varied reasons (such as liquidity needs, portfolio diversification, or profit-taking), they buy for only one reason: an expectation of increased value. However, it is important to remember that an insider purchase is not a guarantee of future stock price appreciation, and you should conduct your own thorough research before making investment decisions.